{"filing":{"accession_number":"0001213900-26-070362","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"ea0295399-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea0295399-8k_moonlake.htm"},"events":[{"id":12560,"run_id":11139,"accession_number":"0001213900-26-070362","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"MoonLake disclosed Week 52 Phase 3 VELA trial results for sonelokimab in hidradenitis suppurativa, showing 67.2% HiSCR75 response and 26.0% inflammatory remission, along with interim Week 24 adolescent data (~68% HiSCR75 response). The company announced plans to submit a Biologics License Application (BLA) to the FDA by end of September 2026, representing a material clinical development milestone with significant regulatory and commercial implications.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9441,"accession_number":"0001213900-26-070362","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MoonLake disclosed Week 52 Phase 3 clinical trial results for sonelokimab in hidradenitis suppurativa and interim adolescent data, along with an expected BLA submission timeline (end of September 2026). While this is a clinical milestone disclosure rather than a traditional earnings release, the positive efficacy and safety data, combined with the regulatory pathway clarity and anticipated commercialization timeline, represent material operational progress for a clinical-stage biotech company that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:02:11.247472+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9442,"accession_number":"0001213900-26-070362","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MoonLake disclosed Week 52 results from its Phase 3 VELA clinical trials for sonelokimab (SLK) in hidradenitis suppurativa, showing 67.2% of patients achieved HiSCR75 response and 26.0% achieved inflammatory remission (IHS4-100), alongside interim Week 24 data from the VELA-TEEN adolescent trial showing ~68% HiSCR75 response. The company also announced plans to submit a Biologics License Application (BLA) to the FDA by end of September 2026. This is a material clinical milestone disclosure for a clinical-stage biotech company with significant regulatory and commercial implications, but it does not fit neatly into earnings, M\u0026A, governance, or other specific event categories—it is a clinical development milestone that is operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:02:11.247472+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9441,"accession_number":"0001213900-26-070362","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MoonLake disclosed Week 52 Phase 3 clinical trial results for sonelokimab in hidradenitis suppurativa and interim adolescent data, along with an expected BLA submission timeline (end of September 2026). While this is a clinical milestone disclosure rather than a traditional earnings release, the positive efficacy and safety data, combined with the regulatory pathway clarity and anticipated commercialization timeline, represent material operational progress for a clinical-stage biotech company that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:02:11.247472+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-22"},{"id":9442,"accession_number":"0001213900-26-070362","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"MoonLake disclosed Week 52 results from its Phase 3 VELA clinical trials for sonelokimab (SLK) in hidradenitis suppurativa, showing 67.2% of patients achieved HiSCR75 response and 26.0% achieved inflammatory remission (IHS4-100), alongside interim Week 24 data from the VELA-TEEN adolescent trial showing ~68% HiSCR75 response. The company also announced plans to submit a Biologics License Application (BLA) to the FDA by end of September 2026. This is a material clinical milestone disclosure for a clinical-stage biotech company with significant regulatory and commercial implications, but it does not fit neatly into earnings, M\u0026A, governance, or other specific event categories—it is a clinical development milestone that is operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:02:11.247472+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-06-22"}]}